Long Term Study With B2036-PEG
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Inclusion Criteria: - Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009). Exclusion Criteria: - Switching to other therapeutic methods for acromegaly
20 Years - 75 Years
Accepts Healthy Volunteers
Pfizer CT.gov Call Center, ,
Pfizer CT.gov Call Center, Study Director, Pfizer